Piggybacking and IOL is a successful technique

Article

Piggybacking with the Add-On IOL is safe, efficient and reliable for correcting pseudophakic refractive errors.

Piggybacking with the Add-On IOL is safe, efficient and reliable for correcting pseudophakic refractive errors.

A team led by Dr B. Basarir, Beyoglu Eye Education and Research Hospital, Istanbul, Turkey, included 10 eyes of 10 patients with pseudophakic refractive errors. All patients were targeted to achieve a range of refraction between -0.50 to +0.50 D.

Preoperative and postoperative outcome measures included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), endothelial cell count (ECC), anterior chamber depth (ACD), the distance between intraocular lenses and contrast sensitivity measurements under mesopic, scotopic, and scotopic with glare conditions.

The mean preoperative and postoperative UDVA was 0.133±0.12 and 0.73±0.27, respectively. Mean preoperative and postoperative CDVA were 0.77±0.26 and 0.79±0.27, respectively.

The findings revealed the mean preoperative and postoperative ACD to be 3.87±0.91 mm vs. 3.58±1.05 mm, respectively. All patients achieved the target refractive range of -0.50 D to +0.50 D and no complications were recorded.

The abstract, recently published in the European Journal of Ophthalmology can be found here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.